KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming ...

Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

EIK1003-001 (Abstract # CT197): A first-in-human, Phase 1/2 dose escalation, dose-optimization, and dose-expansion trial of PARP1-selective inhibitor EIK1003 in patients with advanced solid tumors.

The following poster presentations will take place during Poster Session I on Friday, May 30, from 3:45–5:30 pm CEST (9:45–11:30 am ET): Links to all presentations can be found on the KalVista ...

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990 ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

Trial-in-progress posters to be featured at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress - - FOG-001, first and only direct inhibitor of ß-cateninTCF4, monotherapy and combinati ...